Phase 2 N=40 A Study of ENMD-2076 in Ovarian Clear Cell Cancers
Ovarian Clear Cell Carcinoma
Primary: Six Month Progression Free Survival Rate — 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=452 A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
Urinary Tract Infections
Primary: Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure — 72.6; 54.6 percentage of participants
Phase 2 N=140 Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Primary: Percentage Change in Whole Brain Volume — 0.288; 0.584 percentage of brain volumen change — p=0.003
Phase 2 N=383 Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 — 62; 27; 31; 23 Participants
Phase 2 N=242 Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Neoplasms, Breast
Primary: The Number of Participants With Central Nervous System (CNS) Best Overall Response — 0; 0; 6; 9 Participants
Phase 2 N=20 Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use
Cocaine Use Disorder · Anxiety
Primary: Cue Reactivity as Assessed by the Attention Bias (AB) Task — 0.524; 0.519 score on a scale
Phase 2 N=7 MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Multiple Myeloma · Kahler Disease · Plasma-Cell Myeloma
Primary: Number of Participants With Dose Limiting Toxicity According to CTCAE Version 4.03 — 4 Participants
Phase 2 N=1 Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
Alopecia Areata · Alopecia Totalis · Alopecia Universalis
Primary: Clinician's Eyebrow Assessment — 0 score on a scale
Phase 2 N=64 A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
Liver Fibrosis · Hepatic Fibrosis · Liver Cirrhosis
Primary: Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score — 25; 14 participants — p=0.73
Phase 2 N=80 Paracervical Block During Office Hysteroscopy
Paracervical Block
Primary: Assessment of Pain on a 10-point Visual Analog Pain Scale During the Procedure. — 4.15; 3.38 Score on a scale — p=<.001
Phase 2 N=24 A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products
Psoriasis Vulgaris
Primary: Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1) — -1.60; -4.96; -3.04; -3.96 score on a scale — p=<0.001
Phase 2 N=5 CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
Congenital Hyperinsulinism
Primary: Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind) — 2; 0 Participants
Phase 2 N=61 Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Heptocellular Cancer · Biliary Tract Neoplasms · Liver Cancer
Primary: Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution — 8; 12; 12; 9 Participants
Phase 2 N=111 Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma · Gastric Cancer
Primary: 6 Month Progression Free Survival (PFS) — 63; 53; 73 percentage of paticipants
Phase 2 N=25 A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Trough Plasma Levels (Ctrough) of Calcitriol — 65.04; 62.53; 61.87; 61.46 Picograms Per Millilitre (pg/mL)